Ublituximab BLA Submitted for Relapsing Forms of Multiple Sclerosis
Ublituximab is an investigational glycoengineered anti-CD20 monoclonal antibody.
Relapsing Remitting Multiple Sclerosis
Probiotic Supplements Tied to Improved Outcomes in Relapsing Remitting MS
In a meta-analysis, researchers analyzed the effects of probiotics on disease progression, depression, general health, and anthropometric measures in patients with relapsing remitting multiple sclerosis.
Dimethyl Fumarate Shows Favorable Long-Term Benefit-Risk Profile in MS
A team of researchers assessed the long-term safety and efficacy of dimethyl fumarate for the treatment of patients with relapsing remitting multiple sclerosis for up to 13 years.
High-Efficacy Disease-Modifying Treatment Superior to Escalation in Relapsing-Remitting MS
Researchers compared the effect of high-efficacy DMTs and treatment escalation with regard to the reduction of confirmed disability worsening rates in relapsing-remitting multiple sclerosis.
SARS-CoV-2 Severity, Outcomes Linked to Age and Multiple Sclerosis Subtype
A team of investigators sought to understand COVID-19 characteristics in people with multiple sclerosis and identify high-risk patients.
CSF Myeloid Microvesicles May Be Biomarkers of MS Neuroinflammation, Disease Course
Study researchers evaluated the diagnostic and prognostic value of myeloid microvesicles as multiple sclerosis biomarkers in the clinical setting.
Structural, Functional MRI Measures Improve Prediction of MS Long-Term Worsening
Study investigators evaluated the value of integrating structural and functional network MRI measures to predict clinical disability deterioration of multiple sclerosis.
The Changing Guidelines on the Role of MRI in Multiple Sclerosis Management
The 2021 MAGNIMS-CMSC-NAIMS provided updated consensus recommendations on MRI use in the management of multiple sclerosis.
Diffuse B-Cell Lymphoma of CNS After Dimethyl Fumarate Treatment in RRMS
This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.
Diffusion MRI May Differentiate Primary Progressive From Relapsing Remitting MS
Study researchers assessed the morphometric and microstructural gray matter differences between primary progressive and relapsing remitting multiple sclerosis.
- Loading...
Loading...
Next post in Multiple Sclerosis
Loading... 
Loading...